BeiGene slides on Shanghai debut as US preps to blacklist some Chinese biotechs
Though it’s already publicly traded in the US and Hong Kong, BeiGene went and triple-listed itself in Shanghai’s stock exchange as well. But early returns …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
